COMEBAC 2: Cohort Follow-up of Survivors of Hospitalization for COVID-19 During the 2nd Wave of the Epidemic in France
Study Details
Study Description
Brief Summary
From July to September 2020, in a first uncontrolled cohort study, 478 patients who were hospitalized at Bicêtre hospital for COVID-19 and who survived were evaluated at 4 months (publication accepted at JAMA). The current project aims to bring together the means to continue this work during the 2nd epidemic wave.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
From 15th July to 18th September, 2020, in a first uncontrolled cohort study (Multi-Expertise Consultation of Bicêtre After Covid-19, COMEBAC), we evaluated at four months the surviving patients who were hospitalized at the Bicêtre hospital for COVID-19 during the 1st wave of the epidemic in France and having survived this hospitalization. This cohort included 478 patients. The article resulting from the analysis of the data collected is accepted for publication in JAMA.
This evaluation, the aim of which was both clinical and scientific, was carried out largely thanks to human and material resources then demobilized because of the epidemic and thanks to the investment of doctors and psychologists who carried out the work in addition to their usual work.
The response to the current call for projects aims to bring together the means to continue this monitoring work during the 2nd epidemic wave, while the means and staff are this time completely mobilized by the care of patients with COVID-19 and other. It also aims to raise funds that will allow an in-depth analysis of the residual symptoms presented by the patients.
The current project aims to continue the work started with the COMEBAC "1st wave" cohort with:
-
The inclusion of patients hospitalized after the 1st wave.
-
An assessment of symptoms according to the SARS-CoV-2 variant.
-
A 12-month follow-up of symptomatic patients during the evaluation in COMEBAC "1st wave".
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Patients from the 1st epidemic wave One year after their discharge from the initial hospitalization, patients who presented symptoms during the evaluation in COMEBAC "1st wave" in summer 2020 will benefit from a telephone assessment on the same schedule as that detailed above. If symptoms persist, they will be called to the day hospital for an assessment similar to the one detailed above. |
Other: Teleconsultation
Teleconsulting physicians will subject patients to a standardized questionnaire that will look for the following symptoms:
General signs: Anorexia, fatigue, new hospitalization, weight loss,
Respiratory signs: recent dyspnoea, chest discomfort, chest pain, new cough, abnormal lung CT scan since discharge
Neurological signs: headache, paraesthesia, anosmia, limb paralysis
Digestive signs: abdominal pain, diarrhoea, constipation, nausea, vomiting
Edition 2021
◌ Cognitive signs using the Q3PC questionnaire (10): memory loss, slowness in reasoning, activity planning or problem solving, concentration, attention difficulties
Other: Outpatient clinic
During a day hospitalization planned during the teleconsultation, patients will benefit from the following multidisciplinary assessment.
General clinical examination
Assessment of the state of health
Respiratory assessment
Pulmonary CT assessment
Cognitive evaluation
Cardiological evaluation
Renal assessment
Immunological evaluation
|
| Patients from the 2nd epidemic wave As during the evaluation carried out during the 1st wave, the detection of persistent symptoms will be done in two stages: During a teleconsultation, to which all eligible patients will be invited, systematically looking for general, neurological, cognitive and respiratory symptoms During a hospitalization in an outpatient clinic to which all survivors who have stayed in an intensive care unit (ICU) will be invited and, among patients who have not stayed in an ICU, those who have residual symptoms detected during the teleconsultation. |
Other: Teleconsultation
Teleconsulting physicians will subject patients to a standardized questionnaire that will look for the following symptoms:
General signs: Anorexia, fatigue, new hospitalization, weight loss,
Respiratory signs: recent dyspnoea, chest discomfort, chest pain, new cough, abnormal lung CT scan since discharge
Neurological signs: headache, paraesthesia, anosmia, limb paralysis
Digestive signs: abdominal pain, diarrhoea, constipation, nausea, vomiting
Edition 2021
◌ Cognitive signs using the Q3PC questionnaire (10): memory loss, slowness in reasoning, activity planning or problem solving, concentration, attention difficulties
Other: Outpatient clinic
During a day hospitalization planned during the teleconsultation, patients will benefit from the following multidisciplinary assessment.
General clinical examination
Assessment of the state of health
Respiratory assessment
Pulmonary CT assessment
Cognitive evaluation
Cardiological evaluation
Renal assessment
Immunological evaluation
|
Outcome Measures
Primary Outcome Measures
- Prevalence of respiratory, cognitive and psychological symptoms presented at 6 months of hospitalization for COVID-19. [6 months]
nature and prevalence of symptoms persisting at 6 months of an episode of COVID-19 requiring hospitalization
Secondary Outcome Measures
- Difference between the prevalence of residual symptoms between patients hospitalized during the 1st wave of the epidemic in France (from the COMEBAC "1st wave" study) and those of the current study [6 months]
risk factors for the various sequelae of COVID-19
- Association between patient characteristics and the prevalence of residual symptoms. [6 months]
effect of the therapeutic changes that occurred between the 1st and 2nd wave of COVID-19 on these persistent symptoms.
- Association between residual symptoms and the type of SARS-CoV-2 variant [6 months]
residual symptoms of COVID-19 according to the SARS-CoV-2 variants responsible
- Prevalence of respiratory, neurological, cognitive and psychological symptoms presented at 6 months of hospitalization for COVID-19 which occurred during the 1st epidemic wave. [6 months]
residual symptoms of COVID-19 one year after COVID-19 that occurred during the 1st epidemic wave
Eligibility Criteria
Criteria
For the 6-month evaluation of patients from the 2nd epidemic wave
-
Inclusion criteria
-
Age ≥18 years old
-
COVID-19 defined either by a reverse transcriptase-polymerase chain reaction (RT-PCR) or by a combination of clinical signs and compatible lung CT scan
-
Hospitalization for COVID-19 after 1st July 2020
-
Living out of the hospital
-
Exclusion criteria
-
Death occurring between index hospitalization and reassessment
-
Patient refusal
-
Discovery of a positive RT-PCR for SARS-CoV-2 during hospitalization for a reason other than COVID-19
-
Nosocomial COVID-19
For the 12-month evaluation of patients from the 1st epidemic wave
- Inclusion criteria
◌ Presence of general, cognitive, psychological and respiratory symptoms during the assessment made at 4 months in COMEBAC "1st wave"
-
Exclusion criteria
-
Death occurring between the evaluation in COMEBAC "1st wave" and the re-evaluation
-
Patient refusal
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Bicetre hospital | Le Kremlin-Bicêtre | France | 94270 |
Sponsors and Collaborators
- Assistance Publique - Hôpitaux de Paris
Investigators
- Principal Investigator: Tai PHAM, Bicêtre Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- COMEBAC 2